Update regarding clinical activities at our research units in relation to the Coronavirus disease outbreak situation
CTC Clinical Trial Consultant AB is closely monitoring the Coronavirus disease (COVID-19) outbreak situation to ensure that every effort is made to protect the health of the volunteers and patients who participate in our studies, our employees and guests.
CTC has as a precautionary measure decided to pause screening of study subjects at our first-in-human unit located at the Uppsala University Hospital (Akademiska sjukhuset), which is in line with the hospital’s recommendation. The decision will apply with immediate effect to all upcoming studies. The unit remains open and operational for ongoing studies in line with our duty of care for volunteers and patients already enrolled. Ongoing dose cohorts will be completed and the studies will be paused thereafter.
Our non-hospital based clinical research units (Oscar and Brigaden) currently remains operational and will continue to screen for new subjects.
CTC follows the advice and recommendations issued by the Swedish Public Health Authority and by the Medical Products Agency. Based on these recommendations, CTC has released an internal company-specific policy outlining how our employees should act in case of development of influenza-like symptoms and in relation to traveling, external visits, conferences and research subjects. In case that we face a situation with infected staff or research subjects at CTC, it may have influence on deliverables (recruitment, timetables, available beds in the unit etc.). New measures may be taken on a day-to-day basis in accordance with recommendations given by the authorities.
“Our thoughts are with those affected by this outbreak and we appreciate all healthcare workers and others around the world who are working tirelessly to solve the situation under very difficult conditions” says Anders Millerhovf, CEO.